Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AMG 133 in Healthy Japanese and Caucasian Subjects
NCT05056246Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (5 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration of Intact AMG 133, Maximum Observed Plasma Concentration of Total AMG 133 and 4 more. Started Sep 2021; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05056246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056246.